APA (7th ed.) Citation

J, O., J, P., B, T., A, D. A., E, M., J, D. l. T., . . . J, G. (2018). Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: Data at 24 weeks. BMC pharmacology & toxicology, 19(1), 63. https://doi.org/10.1186/s40360-018-0252-z

Chicago Style (17th ed.) Citation

J, Olalla, et al. "Efficacy and Safety of the Switch of Triumeq® to Generic (abacavir + Lamivudine) + Tivicay®: Data at 24 weeks." BMC Pharmacology & Toxicology 19, no. 1 (2018): 63. https://doi.org/10.1186/s40360-018-0252-z.

MLA (9th ed.) Citation

J, Olalla, et al. "Efficacy and Safety of the Switch of Triumeq® to Generic (abacavir + Lamivudine) + Tivicay®: Data at 24 weeks." BMC Pharmacology & Toxicology, vol. 19, no. 1, 2018, p. 63, https://doi.org/10.1186/s40360-018-0252-z.